• Active, not recruiting

NCT01346787: EMN - Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone Newly Diagnosed Myeloma

Updated: Sep 25

EMN

European Myeloma Network

NCT01346787: Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (CCD)

ccd myeloma emn

The purpose of this study is to determine whether the association of Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) as induction treatment is safe and provides benefits in patients with newly diagnosed Multiple Myeloma (MM).


Sponsor

European Myeloma Network


Collaborator

Fondazione EMN Italy Onlus

 

ClinicalTrials.gov Identifier: NCT01346787

Official Title: A MULTICENTER, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

IST-CAR-506

First Posted : May 3, 2011

Click here for details on ClinicalTrials.gov

 

Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information


Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information


Cyclophosphamide : National Cancer Institute

Cyclophosphamide : MedlinePlus Drug Information

Cyclophosphamide IV : MedlinePlus Drug Information

 

Drug: CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE

 

Haematologica;2021

Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies

https://pubmed.ncbi.nlm.nih.gov/32107329/


Haematologica;2020

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs

https://pubmed.ncbi.nlm.nih.gov/31221778/


Haematologica;2019

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies

Once-weekly 70 mg/m2 carfilzomib as induction and maintenance therapy for newly diagnosed multiple myeloma patients was as safe and effective as twice-weekly 36 mg/m2 carfilzomib and provided a more convenient schedule. The trials are registered at clinicaltrials.gov

https://pubmed.ncbi.nlm.nih.gov/30733270/


Blood;2015

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

http://www.myelomafrailtyscorecalculator.net/

https://pubmed.ncbi.nlm.nih.gov/25628469/


Blood;2014

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

In summary, results showed high complete response rates and a good safety profile. This trial was registered at clinicaltrials.gov

https://pubmed.ncbi.nlm.nih.gov/24855212/

 

Locations

Europe

Italy

Netherlands





Posts Archive